The National Institute of Standards and Technology (NIST) introduced a Draft Interagency Guidance
Framework for Considering the Exercise of March-In Rights that sets out to clarify the guidelines by
which march-in rights can be exercised. The new guidance expands the government’s discretion of
march-in rights in a way that will lead to a variety of industries facing ramifications. The Biden
administration’s aggressive agenda to lower the cost of prescription drugs disregards the negative side
effects creating a hesitation by industries to enter government partnerships and ultimately a hindrance
to innovation and development.
